Extended-spectrum beta-lactamases and plasmid-mediated AmpC enzymes among clinical isolates of Escherichia coli and Klebsiella pneumoniae from seven medical centers in Taiwan.

Antimicrobial Agents and Chemotherapy
Jing-Jou YanJiunn-Jong Wu

Abstract

Production of extended-spectrum beta-lactamases and plasmid-mediated AmpC enzymes was investigated among 291 Escherichia coli and 282 Klebsiella pneumoniae isolates that showed decreased susceptibilities to extended-spectrum cephalosporins from seven Taiwanese medical centers. CTX-M-type and SHV-type enzymes were the most prevalent extended-spectrum beta-lactamases. CMY-2-like and DHA-1-like beta-lactamases were the most prevalent AmpC-type enzymes.

References

May 1, 1996·European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology·M T Nüesch-InderbinenF H Kayser
Feb 7, 2001·The Journal of Antimicrobial Chemotherapy·N FortineauP Nordmann
Dec 26, 2001·Antimicrobial Agents and Chemotherapy·Alain PhilipponGeorge A Jacoby
Dec 25, 2003·Antimicrobial Agents and Chemotherapy·R Bonnet

❮ Previous
Next ❯

Citations

Feb 14, 2009·European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology·H M ChenJ J Yan
Sep 18, 2010·European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology·U-I WuY-C Chen
Jan 18, 2012·European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology·N Y LeeJ J Yan
Feb 5, 2011·Journal of Microbiology, Immunology, and Infection = Wei Mian Yu Gan Ran Za Zhi·Chih-Chauan KaoZhi-Yuan Shi
Aug 7, 2010·Journal of Microbiology, Immunology, and Infection = Wei Mian Yu Gan Ran Za Zhi·Un-In WuShan-Chwen Chang
Jul 14, 2010·Microbial Drug Resistance : MDR : Mechanisms, Epidemiology, and Disease·Joanna EmpelMarek Gniadkowski
Mar 1, 2011·Microbial Drug Resistance : MDR : Mechanisms, Epidemiology, and Disease·Jiunn-Jong WuJing-Jou Yan
Mar 8, 2012·Microbial Drug Resistance : MDR : Mechanisms, Epidemiology, and Disease·Wing Sze HoKwai Lin Thong
Jul 30, 2009·The Journal of Antimicrobial Chemotherapy·L F MatasejeUNKNOWN Canadian Public Health Laboratory Network (CPHLN)
May 7, 2008·Antimicrobial Agents and Chemotherapy·Joanna EmpelUNKNOWN Beta-PL Study Group
Jan 13, 2009·Clinical Microbiology Reviews·George A Jacoby
Jul 9, 2010·Journal of Clinical Microbiology·Katsutoshi YamasakiYoshimasa Yamamoto
Mar 21, 2015·PloS One·Jann-Tay WangShan-Chwen Chang
Dec 11, 2021·Microbial Drug Resistance : MDR : Mechanisms, Epidemiology, and Disease·Djahida SounaMax Maurin

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Antimicrobial Resistance (ASM)

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.

Antimicrobial Resistance

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.

CRISPR Screens in Drug Resistance

CRISPR-Cas system enables the editing of genes to create or correct mutations. This feed focuses on the application of CRISPR-Cas system in high-throughput genome-wide screens to identify genes that may confer drug resistance.

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.